As for patients with KRAS mutant tumors, the difference in median OS between patients with or without BTx did not reach statistical significance (median OSs were 5.8 vs. 3.1 months, respectively; P=0.35; Figure 3A ).
← all excerpts
The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation.
2
0.3500
0.3500
The sentences
In contrast, KRAS mutational status curves remain separated for the entire survival range and thus KRAS status has a highly significant impact on survival both by Mantel-Cox and Gehan-Breslow-Wilcoxon tests.